Unlock the Secret to a Longer, Leaner Life: The Surprising Truth Behind Elon Musk’s Go-To ‘Diet Pill’ and Its Anti-Aging Benefits
Breakthrough Study Reveals Wegovy and Ozempic’s Potential to Slow Down Human Aging and Lower Mortality Rates
A groundbreaking study has found that Wegovy and Ozempic, commonly referred to as ‘diet pills’ used by celebrities such as Tesla CEO Elon Musk and American influencer Kim Kardashian, have the potential to slow down human aging and lower mortality rates.
According to a report by the British media BBC, the research results were announced at the European Society of Cardiology conference held in London. Semaglutide, the main ingredient in Wegovi and Ozempic developed by the Danish pharmaceutical company Novo Nordisk, has been found to have a wide range of benefits, including the treatment of cancer, Alzheimer’s, heart disease, and arthritis.
The study, conducted by a joint research team including Harvard University, involved 17,604 people aged 45 or older who were overweight or obese and had cardiovascular disease but no diabetes. The participants were divided into two groups: one that took semaglutide once a week and another that took a placebo. The study found that the semaglutide group had a 19% lower mortality rate from all causes, including cardiovascular problems, compared to the placebo group.
The semaglutide group also showed a continuous decrease in disease problems, such as improved heart failure symptoms and lowered inflammation levels in the body. Additionally, semaglutide had a similar probability of COVID-19 infection in the treatment group to the placebo group, but a lower risk of death from COVID-19.
Harvard University professor Benjamin Schirica, one of the paper’s lead authors, stated, “This study supports the idea that being overweight and obese increases the risk of death from multiple causes. It’s particularly striking that deaths from infections were reduced in the semaglutide group.”
Harlan Krumholz, a professor at Yale School of Medicine who also published the study, noted, “It has broader benefits than we first imagined. It’s not just about preventing heart attacks, it’s about improving health. By improving people’s health in this way, it can actually delay the aging process. This drug should now be considered not just a weight-loss aid, but a multipurpose drug and health-promoting agent.”
Wegovi and Ozempic were initially developed as diabetes treatments but are now used as diet drugs due to their excellent weight loss effects. Wegovi was approved as an obesity treatment by the U.S. Food and Drug Administration (FDA) in June 2021 and is expected to be released in Korea in October of this year.